Amyloban 3399 (Lion's Mane Standardized Mycelium Extract)

Overview

Amyloban 3399 is a proprietary standardized extract of Hericium erinaceus (Lion’s Mane) mycelium, manufactured by Mushroom Wisdom, Inc. (formerly Maitake Products, Inc., East Rutherford, NJ, USA). It is standardized to contain amycenone, a compound identified by the manufacturer as a unique bioactive constituent of Lion’s Mane mycelium, alongside the established neurotrophic compounds hericenones and erinacines.

Amyloban 3399 is pharmacologically distinct from whole Lion’s Mane fruiting body products and from generic mycelium-on-grain preparations. Its clinical evidence, while limited in volume, targets psychiatric and neurocognitive indications (treatment-resistant depression, neurocognitive disorders) that go beyond the cognitive enhancement focus of the broader Lion’s Mane literature. The product name “Amyloban” references its purported activity against amyloid-beta protein aggregation, relevant to Alzheimer’s disease pathology.

Parent species monograph: For comprehensive coverage of Hericium erinaceus (Lion’s Mane) including the NGF/BDNF neurotrophic mechanism, hericenone and erinacine pharmacology, the Mori et al. (2009) landmark RCT, and the fruiting body vs. mycelium distinction, see the Lion’s Mane monograph.

Composition and Key Bioactives

Amycenone

Amycenone is the distinguishing bioactive claimed by the manufacturer. It is described as a lipophilic compound derived from H. erinaceus mycelium that demonstrates anti-amyloid-beta aggregation activity in vitro and neuroprotective effects in cellular models. However, the chemical identity and structure of amycenone have not been fully disclosed in peer-reviewed literature, and independent verification of the compound’s identity and activity is limited. The manufacturer holds proprietary claims over this fraction.

It is important to note that amycenone may overlap with or include known erinacine compounds. Without full structural disclosure, the relationship between amycenone and the well-characterized erinacine family cannot be determined with certainty.

The Mycelium Advantage for Lion’s Mane

Lion’s Mane is the most prominent exception to the general “fruiting body preferred” rule in medicinal mycology. The mycelium and fruiting body of H. erinaceus contain complementary but different neurotrophic compound classes:

• Fruiting body: Hericenones (C, D, E, F, G, H) — aromatic phenylpropanoid NGF stimulators. Limited evidence for blood-brain barrier penetration.
• Mycelium: Erinacines (A, B, C, E, F, G, H, I) — cyathane diterpenoid NGF stimulators. Confirmed to cross the blood-brain barrier. More potent NGF induction per mole than hericenones in in vitro assays.

This dual compound profile is the reason the parent Lion’s Mane monograph classifies the species as “both-effective” for fruiting body vs. mycelium preference. Amyloban 3399 focuses specifically on the mycelium-derived bioactive profile.

Clinical Evidence

The clinical evidence for Amyloban 3399 specifically is limited to publications from a single clinical group (Inanaga and colleagues) in Japan. While the studies are small and methodologically limited, they address psychiatric indications not covered by other Lion’s Mane clinical trials.

Treatment-Resistant Depression

Key details of the Inanaga (2014) study:

• Population: 8 patients diagnosed with treatment-resistant major depression (DSM-IV criteria) who had failed adequate trials of at least two different antidepressant medications.
• Intervention: Amyloban 3399 added to existing antidepressant regimens (not as monotherapy). Dose details were specified per manufacturer recommendations.
• Assessment: Hamilton Depression Rating Scale (HAM-D) at baseline, weeks 4 and 8.
• Results: Mean HAM-D scores decreased significantly from baseline. Six of eight patients showed clinically meaningful improvement (>50% reduction in HAM-D score). Two patients met criteria for remission (HAM-D < 7).
• Mechanistic hypothesis: The authors proposed that NGF/BDNF stimulation via erinacines may support hippocampal neurogenesis and synaptic plasticity — processes implicated in antidepressant response and known to be impaired in treatment-resistant depression.

Neurocognitive Disorders

Context Within the Broader Lion’s Mane Evidence Base

Amyloban 3399’s clinical data should be considered alongside the broader Lion’s Mane clinical evidence:

The Li et al. (2020) trial is the most relevant comparison. That study used an erinacine A-enriched H. erinaceus mycelium preparation (different from Amyloban 3399 but conceptually similar — a standardized mycelium extract targeting the erinacine fraction) and demonstrated significant cognitive improvements in the largest and longest Lion’s Mane RCT to date (n=77, 49 weeks). The Li et al. results provide independent support for the therapeutic potential of standardized Lion’s Mane mycelium extracts for neurocognitive indications.

Mechanism of Action

NGF and BDNF Stimulation

The primary proposed mechanism for Amyloban 3399 is identical to the core Lion’s Mane neurotrophic mechanism: stimulation of endogenous nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) synthesis through erinacine-mediated gene expression in astrocytes and glial cells. Erinacines cross the blood-brain barrier and directly activate neurotrophic signaling in the central nervous system. This mechanism supports:

• Hippocampal neurogenesis: New neuron formation in the hippocampus, critical for learning, memory, and mood regulation.
• Synaptic plasticity: Enhanced long-term potentiation and synaptic connectivity.
• Neuronal survival: Protection of existing neurons against apoptosis and excitotoxic damage.
• Remyelination: Promotion of oligodendrocyte precursor cell differentiation and myelin sheath repair.

Anti-Amyloid-Beta Activity

The manufacturer claims that amycenone demonstrates anti-amyloid-beta protein aggregation activity in vitro. Amyloid-beta plaque accumulation is a hallmark pathological feature of Alzheimer’s disease. If confirmed, this activity would complement the neurotrophic mechanism by addressing both the symptomatic (neurotrophic support) and pathological (amyloid burden) dimensions of Alzheimer’s disease. However, this activity has not been validated in human clinical studies, and the anti-amyloid-beta claim should be considered preclinical and preliminary.

Relevance to Treatment-Resistant Depression

The NGF/BDNF-mediated mechanism is particularly relevant to treatment-resistant depression because:

1. BDNF deficiency in depression: Serum BDNF levels are consistently reduced in patients with major depression and are further reduced in treatment-resistant cases.
2. Neurogenesis hypothesis of depression: Impaired hippocampal neurogenesis is implicated in the pathophysiology of depression and in antidepressant resistance.
3. Complementary mechanism: Standard antidepressants (SSRIs, SNRIs) modulate monoamine neurotransmission. Lion’s Mane mycelium acts through a completely different mechanism (neurotrophic factor stimulation), providing a rationale for additive benefit when used as adjunctive therapy.
4. Temporal profile: The Mori et al. (2009) finding that cognitive benefits required 8+ weeks of supplementation and reversed after discontinuation is consistent with a neurogenesis-based mechanism, which requires sustained neurotrophic stimulation.

Safety Profile

General Assessment

Hericium erinaceus mycelium preparations have demonstrated an excellent safety profile across all published studies. Subchronic toxicity studies in rats showed no adverse effects at doses up to 3 g/kg/day for 90 days (Li et al. 2014). The whole Lion’s Mane mushroom has GRAS status in the United States and has centuries of culinary use in East Asia.

Adverse Effects

• No adverse effects were reported in the Inanaga (2012, 2014) studies.
• The broader Lion’s Mane literature reports no serious adverse events across all published clinical trials.
• Mild gastrointestinal discomfort (nausea, abdominal bloating) has been reported rarely in post-marketing experience with various Lion’s Mane products.

Drug Interactions

No clinically documented drug interactions specific to Amyloban 3399 have been reported. Theoretical considerations:

• Antidepressant medications: Amyloban 3399 was used as adjunctive therapy with existing antidepressants in the Inanaga (2014) study with no adverse interactions reported. However, given the small sample size, this does not conclusively rule out interactions.
• Immunosuppressants: Beta-glucan content may theoretically counteract immunosuppressive therapy, though Amyloban 3399 is not marketed primarily for immune modulation.
• Anticoagulants/antiplatelets: Theoretical mild additive antiplatelet effect based on in vitro data for H. erinaceus polysaccharides. Clinical significance is unknown.

Contraindications

• Known allergy to Hericium erinaceus or Basidiomycota mushrooms.
• Pregnancy and lactation: Insufficient safety data; avoid.
• Discontinuation note: The Mori et al. (2009) finding that cognitive benefits reverse within 4 weeks of discontinuation should be communicated to patients to set appropriate expectations.

Dosage

Manufacturer Recommendation

• Standard dose: Typically 3—6 tablets/day of Amyloban 3399 (specific mg per tablet varies by product formulation; follow manufacturer label).
• Timing: Usually taken with meals.

Clinical Study Doses

• The exact dose in the Inanaga (2014, 2012) studies was reported per manufacturer specifications. Detailed mg/day breakdowns were not standardized to erinacine or amycenone content in the published reports.

Comparison with Other Lion’s Mane Mycelium Products

• Li et al. (2020) erinacine A-enriched mycelium: 350 mg capsules, 3x/day, standardized to 5 mg/g erinacine A. This is currently the most well-characterized mycelium dosing protocol.
• Mori et al. (2009) fruiting body powder: 3 g/day. Different compound profile (hericenones, not erinacines).

For cognitive and neuropsychiatric indications, mycelium-derived products standardized to erinacine content are theoretically preferred over fruiting body products, because erinacines are more potent NGF inducers and have confirmed blood-brain barrier penetration. However, the Li et al. (2020) erinacine A-enriched mycelium preparation is better characterized and clinically validated than Amyloban 3399.

Distinction from Other Lion’s Mane Products

Evidence Limitations

The evidence for Amyloban 3399 specifically has significant limitations that must be clearly acknowledged:

• Very small sample sizes: The depression study included only 8 patients; the neurocognitive case series included only 4. These sample sizes are insufficient to establish efficacy.
• No blinding or placebo control: Both studies were open-label. Placebo effects are particularly significant in depression trials, where placebo response rates of 30—40% are typical.
• Single research group: All Amyloban 3399-specific clinical data comes from Inanaga and colleagues. Independent replication is entirely absent.
• Proprietary bioactive: Amycenone has not been fully structurally characterized in peer-reviewed literature. Its relationship to known erinacine compounds is unclear. Independent analytical verification is not possible without full structural disclosure.
• No dose-response data: Optimal dosing has not been established through systematic dose-ranging studies.
• Manufacturer-funded research: The relationship between the clinical investigators and the manufacturer is not always transparent in published reports, raising potential conflict-of-interest concerns.
• The Li et al. (2020) trial provides stronger evidence for Lion’s Mane mycelium in cognitive indications — it was double-blind, placebo-controlled, larger (n=77), longer (49 weeks), and used a well-characterized erinacine A-standardized preparation. This makes the case for Lion’s Mane mycelium extracts in general, but does not specifically validate Amyloban 3399.

Despite these limitations, the Amyloban 3399 data is noteworthy because it provides the only published clinical evidence for Lion’s Mane in treatment-resistant depression — a particularly difficult clinical population with significant unmet therapeutic need. The mechanistic rationale (BDNF-mediated neurogenesis complementing monoamine-based antidepressants) is scientifically sound, and the case for further investigation is compelling.

Sources

• Inanaga K. Marked improvement of neurocognitive impairment after treatment with compounds from Hericium erinaceum: a case series of dementia patients. Pers Med Universe. 2012;1(1):73-76
• Inanaga K. Amycenone, a nootropic found in Hericium erinaceum: open-label study of treating depression. Pers Med Universe. 2014;3:80-82
• Li IC, Chang HH, Lin CH, et al. Prevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Front Aging Neurosci. 2020;12:155
• Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372
• Nagano M, Shimizu K, Kondo R, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010;31(4):231-237
• Kawagishi H, Shimada A, Shirai R, et al. Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Lett. 1994;35(10):1569-1572
• Kawagishi H, Ando M, Sakamoto H, et al. Hericenones C, D and E, stimulators of nerve growth factor (NGF)-synthesis, from the mushroom Hericium erinaceum. Tetrahedron Lett. 1991;32(35):4561-4564
• Chiu CH, Chyau CC, Chen CC, et al. Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3beta signaling in mice. Int J Mol Sci. 2018;19(2):341
• Li IC, Chen YL, Lee LY, et al. Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague-Dawley rats. Food Chem Toxicol. 2014;70:61-67
• Friedman M. Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (lion’s mane) mushroom fruiting bodies and mycelia and their bioactive compounds. J Agric Food Chem. 2015;63(32):7108-7123
• Tsai-Teng T, Chin-Chu C, Li-Ya L, et al. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer’s disease-related pathologies in APPswe/PS1dE9 transgenic mice. J Biomed Sci. 2016;23(1):49
• Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019;40(4):125-131